Myelophthistic anemia: Difference between revisions

No edit summary
Line 1: Line 1:
==Background==
==Background==
*Form of normocytic anemia
*Form of normocytic anemia
*Associated with infiltrative disorder of bone marrow in the setting of malignancy--invasive tumor, leukemia, lymphoma, granuloma
*Infiltrative disorder of bone marrow in the setting of malignancy--invasive tumor, leukemia, lymphoma, granuloma
 
==Clinical Features==
==Clinical Features==
*Most pts begin to be symptomatic at ~7gm/dL
*Most pts begin to be symptomatic at ~7gm/dL

Revision as of 18:01, 3 August 2015

Background

  • Form of normocytic anemia
  • Infiltrative disorder of bone marrow in the setting of malignancy--invasive tumor, leukemia, lymphoma, granuloma

Clinical Features

  • Most pts begin to be symptomatic at ~7gm/dL
  • Weakness, fatigue, lethargy, DOE, palpitations
  • Skin, nail bed, mucosal pallor
  • Widened pulse pressure
  • Tachycardia/hypotension in severe cases
  • Hepatosplenomegaly as sign of extra medullary hematopoiesis

Differential Diagnosis

  • Aplastic anemia
  • Myelofibrosis
  • Acute blood loss anemia
  • Bone marrow suppression
  • Anemia of chronic disease
  • Hemolytic anemia

Diagnosis

  • Requires bone marrow biopsy
  • Labs show normocytic anemia with decreased reticulocyte count
  • Exam with signs of extra medullary hematopoiesis
  • Index of suspicion in setting of malignancy + anemia

Management

  • Identify anemia as emergent or non-emergent
  • Evaluate for superimposed etiologies of anemia (Ie acute blood loss) and target treatment in the ED
  • If emergent anemia get IV access, transfuse for signs of end organ damage--AMS, hypotension, chest pain, shortness of breath, decreased UOP
  • Will need treatment of underlying malignancy to allow marrow recovery while supporting hemodynamics

Disposition

  • Admit for bone marrow biopsy and treatment of underlying disease

See Also

External Links

References